Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

765
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
765
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.3K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.3K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Current pharmacological challenges of Treatment-Resistant Depression.

Pharmacological research·2026
Same author

From the Scientific Underground to the Height of Recognition: The 40th Anniversary of Rita Levi-Montalcini's Nobel Prize and the Promising Horizon in Psychiatry.

Neurochemical research·2026
Same author

Kenneth Bancroft Clark and the moral arc of psychological science: Reflections 20 years after his passing.

Journal of the history of the neurosciences·2026
Same author

Bridging Local Realities and Global Science: Psychiatric Education at 35 Years of Brazil's Sistema Único de Saúde.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)·2026
Same author

Nathan S. Kline: From the first treatments of psychosis and depression, a 70-year legacy of a pioneer of psychopharmacology.

Journal of psychopharmacology (Oxford, England)·2026
Same author

The role of hypothyroidism in the resilience against depressive episodes during covid pandemic in a cohort of old adults.

Frontiers in psychiatry·2026

Related Experiment Video

Updated: Jan 7, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

493

Antidepressants: bleeding or thrombosis?

Silvia Hoirisch-Clapauch1, Antonio E Nardi2

  • 1Hospital Federal dos Servidores do Estado, Ministry of Health, Rio de Janeiro, Brazil.

Thrombosis Research
|September 4, 2019
PubMed
Summary
This summary is machine-generated.

Serotonergic antidepressants may act as weak anticoagulants by reducing platelet adhesion and restoring fibrinolysis. This mechanism may explain both reduced cardiovascular events and increased bleeding risks associated with these drugs.

Keywords:
AntidepressantsBleedingCardiovascular diseasesSelective serotonin reuptake inhibitorsSerotonin and noradrenaline reuptakeThrombosisTricyclic antidepressantsinhibitors

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.3K

Related Experiment Videos

Last Updated: Jan 7, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

493
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.9K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.3K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Neuroscience

Background:

  • Depression contributes to cardiovascular disease through autonomic dysfunction, inflammation, and impaired fibrinolysis.
  • Serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), may influence cardiovascular risk.
  • The precise impact of these antidepressants on thrombotic and cardiovascular events remains debated.

Purpose of the Study:

  • To investigate the role of serotonergic antidepressants in cardiovascular disease pathogenesis.
  • To elucidate the mechanisms by which these antidepressants affect fibrinolysis and platelet function.
  • To reconcile contradictory findings regarding the cardiovascular and thromboembolic risks associated with serotonergic antidepressant use.

Main Methods:

  • Review of existing evidence on depression, cardiovascular disease, and serotonergic antidepressants.
  • Analysis of the effects of SSRIs and SNRIs on fibrinolytic profiles and platelet aggregation/adhesion.
  • Evaluation of studies reporting cardiovascular and thromboembolic outcomes in patients using these medications.

Main Results:

  • Serotonergic antidepressants appear to restore fibrinolytic profiles and reduce platelet adhesion to collagen, potentially via interactions with the glycoprotein VI receptor.
  • These profibrinolytic and antiplatelet effects may contribute to both reduced thrombotic events and increased bleeding risks (gastrointestinal, intracranial, surgical).
  • Contradictory findings exist regarding overall cardiovascular and thromboembolic risk, with some studies showing benefit and others showing increased risk, possibly due to side effects or comorbidities.

Conclusions:

  • Serotonergic antidepressants can be considered weak anticoagulants due to their effects on fibrinolysis and platelet adhesion.
  • Depressed patients with cardiovascular risk factors should be advised on lifestyle modifications like diet and exercise.
  • Further research is needed to fully clarify the complex relationship between serotonergic antidepressants, thrombosis, and cardiovascular outcomes.